U.S. markets close in 1 hour 30 minutes
  • S&P 500

    3,298.83
    -91.85 (-2.71%)
     
  • Dow 30

    26,707.39
    -755.80 (-2.75%)
     
  • Nasdaq

    11,107.89
    -323.46 (-2.83%)
     
  • Russell 2000

    1,546.72
    -43.76 (-2.75%)
     
  • Crude Oil

    37.30
    -2.27 (-5.74%)
     
  • Gold

    1,878.60
    -33.30 (-1.74%)
     
  • Silver

    23.39
    -1.18 (-4.80%)
     
  • EUR/USD

    1.1759
    -0.0030 (-0.26%)
     
  • 10-Yr Bond

    0.7690
    -0.0090 (-1.16%)
     
  • GBP/USD

    1.2992
    -0.0049 (-0.38%)
     
  • USD/JPY

    104.3020
    -0.1920 (-0.18%)
     
  • BTC-USD

    13,189.42
    -505.87 (-3.69%)
     
  • CMC Crypto 200

    260.81
    -11.88 (-4.36%)
     
  • FTSE 100

    5,582.80
    -146.19 (-2.55%)
     
  • Nikkei 225

    23,418.51
    -67.29 (-0.29%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fennec Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 2, 2020 - FENC

Newsfile Corp.
·2 mins read

New York, New York--(Newsfile Corp. - September 23, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Fennec Pharmaceuticals Inc. ("Fennec") (NASDAQ: FENC) between February 11, 2020 and August 10, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Middle District of North Carolina. To get more information go to:

https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-information-request-form?prid=9537&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you suffered a loss in Fennec you have until November 2, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64495